Biosensor-Enabled Discovery of CaERG6 Inhibitors and Their Antifungal Mode of Action against Candida albicans .
Zhan LiuYi LiDaijing WeiJing WangChong QiaoGuo-You LiGuolin ZhangYinggang LuoPublished in: ACS infectious diseases (2023)
Fungal infections caused by opportunistic pathogens, such as Candida albicans , are generally underappreciated by the public in spite of their high mortality rates. Antifungal arsenals are extremely limited. Herein, based on biosynthetic pathway comparison and functional characterization, CaERG6, a crucial sterol 24-C-methyltransferase involved in the biosynthesis of ubiquitous ergosterol in C. albicans , was set up as an antifungal target. CaERG6 inhibitors were identified from the in-house small-molecule library by a biosensor-based high-throughput screening. The CaERG6 inhibitor NP256 (palustrisoic acid E) is a potential antifungal natural product that acts by inhibiting ergosterol biosynthesis, downregulating the gene expression level in hyphal formation, blocking biofilm formation, and disrupting morphological transition in C. albicans . NP256 enhances C. albicans susceptibility to some known antifungals significantly. The present study demonstrated the CaERG6 inhibitor NP256 as a potential class of antifungal compound for monotherapy or combinatory therapy.
Keyphrases
- candida albicans
- biofilm formation
- small molecule
- gene expression
- gold nanoparticles
- sensitive detection
- healthcare
- pseudomonas aeruginosa
- type diabetes
- cell wall
- cardiovascular disease
- mental health
- emergency department
- dna methylation
- high throughput
- gram negative
- climate change
- cardiovascular events
- mesenchymal stem cells
- human health
- risk factors
- label free
- staphylococcus aureus
- stem cells
- cell therapy
- clinical evaluation